Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Grant or award Director acquired 6,869 shares (grant or award)
  2. 3 Insider Initial Statement of Ownership
  3. 8-K Event Executive or director change
  4. SC 13G/A Stake Amended Statement of Ownership
  5. SC 13G/A Stake Amended Statement of Ownership
  6. 4 Grant or award Director acquired 627 shares (grant or award)
  7. 8-K Event Regulation FD disclosure
  8. 4 Open-market sale President and CEO sold 5,007 shares at $44.78 ($224,213)
  9. 4 Open-market sale CFO and Treasurer sold 2,225 shares at $44.75 ($99,569)
  10. 4 Open-market sale Chief Medical Officer sold 2,845 shares at $44.78 ($127,399)
  11. 4 Open-market sale COO and Secretary sold 2,846 shares at $44.77 ($127,415)
  12. 4 Grant or award COO and Secretary acquired 31,000 shares (grant or award)
  13. 4 Grant or award Chief Medical Officer acquired 31,000 shares (grant or award)
  14. 4 Grant or award President and CEO acquired 62,000 shares (grant or award)
  15. 4 Grant or award CFO and Treasurer acquired 31,000 shares (grant or award)
  16. 4 Open-market sale Director sold 63,131 shares at an average $44.43 ($2,805,197)
  17. 4 Open-market sale COO and Secretary sold 10,000 shares at an average $42.27 ($422,736)
  18. 4 Open-market sale Chief Medical Officer sold 1,476 shares at $42.52 ($62,760)
  19. 4 Open-market sale President and CEO sold 18,333 shares at an average $44.92 ($823,581)
  20. 8-K Event Regulation FD disclosure

Page 21 of 40 · 789 filings